Linked Life Data

11387156

Source:http://linkedlifedata.com/resource/pubmed/id/11387156

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11387156rdf:typepubmed:Citationlld:pubmed
pubmed-article:11387156lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:11387156lifeskim:mentionsumls-concept:C0278996lld:lifeskim
pubmed-article:11387156lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:11387156lifeskim:mentionsumls-concept:C0002475lld:lifeskim
pubmed-article:11387156lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:11387156lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:11387156lifeskim:mentionsumls-concept:C0205187lld:lifeskim
pubmed-article:11387156lifeskim:mentionsumls-concept:C0521115lld:lifeskim
pubmed-article:11387156pubmed:issue880lld:pubmed
pubmed-article:11387156pubmed:dateCreated2001-6-6lld:pubmed
pubmed-article:11387156pubmed:abstractTextThe feasibility and effectiveness of a combined chemoradiotherapy treatment modality for locally advanced head and neck cancer was tested in a phase II trial. From March 1995 to June 1998, 35 patients with advanced squamous cell carcinoma of the head and neck were treated with a continuous intravenous infusion of 5-fluorouracil (600 mg m-2 24 h-1 for Days 1 to 5 (120 h)) and mitomycin-C (10 mg m-2 intravenously) on Day 5 during the first week of radiotherapy and on Day 36. 31 patients had stage IV disease; 4 patients had stage III; and 1 patient had stage II. Patient ages ranged from 42-69 years (median 56.7 years). The tumours involved were as follows: oral cavity (n = 11); oropharynx (n = 14); hypopharynx/larynx (n = 10). Radiotherapy was delivered to a total dose of 70 Gy with conventional fractionation (2 Gy per fraction, five times a week). Chemotherapy was well tolerated and all patients received the intended dose. Mild nausea occurred in five patients. After a mean follow-up of 21 months (range 10-44 months), 8 (23%) patients remain alive. A complete response was seen in 28 (80%) patients. When a recurrence appeared, it was within the first year after treatment. 1- and 2-year overall survival rates were 46% and 23%, respectively. Grade 3 mucositis occurred in 17% of patients. Grade 1-2 thrombopaenia occurred in 3 (9%) patients, grade > 2 leukopaenia in 4 (11%) patients, and grade > or = 2 anaemia in 3 (9%) patients. We observed a treatment interruption of maximum 1 week for six patients owing to mucositis. Febrile neutropaenia or aplasia were not observed. The concomitant use of 5-fluorouracil, mitomycin-C and radiotherapy in locally advanced head and neck carcinoma is well tolerated in this group of patients. This protocol showed good locoregional response with a very low toxicity profile.lld:pubmed
pubmed-article:11387156pubmed:languageenglld:pubmed
pubmed-article:11387156pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11387156pubmed:citationSubsetAIMlld:pubmed
pubmed-article:11387156pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11387156pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11387156pubmed:statusMEDLINElld:pubmed
pubmed-article:11387156pubmed:monthAprlld:pubmed
pubmed-article:11387156pubmed:issn0007-1285lld:pubmed
pubmed-article:11387156pubmed:authorpubmed-author:WeissEElld:pubmed
pubmed-article:11387156pubmed:authorpubmed-author:EberleinKKlld:pubmed
pubmed-article:11387156pubmed:authorpubmed-author:HessC FCFlld:pubmed
pubmed-article:11387156pubmed:authorpubmed-author:PradierOOlld:pubmed
pubmed-article:11387156pubmed:authorpubmed-author:JackelM CMClld:pubmed
pubmed-article:11387156pubmed:issnTypePrintlld:pubmed
pubmed-article:11387156pubmed:volume74lld:pubmed
pubmed-article:11387156pubmed:ownerNLMlld:pubmed
pubmed-article:11387156pubmed:authorsCompleteYlld:pubmed
pubmed-article:11387156pubmed:pagination368-74lld:pubmed
pubmed-article:11387156pubmed:dateRevised2006-4-24lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:meshHeadingpubmed-meshheading:11387156...lld:pubmed
pubmed-article:11387156pubmed:year2001lld:pubmed
pubmed-article:11387156pubmed:articleTitleRadiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluorouracil for inoperable head and neck cancer.lld:pubmed
pubmed-article:11387156pubmed:affiliationDepartment of Radiotherapy, University of Göttingen, Robert Koch Strasse 40, D 37075 Göttingen, Germany.lld:pubmed
pubmed-article:11387156pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11387156lld:pubmed